Clinical Trial Update: T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating T cells engineered to express a fully-human anti-BCMA CAR for treating multiple myeloma; results were posted in 2023 and the study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Fully-human anti-BCMA CAR-T cells (BCMA-directed chimeric antigen receptor T cells)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Myeloma-Multiple, Myeloma, Plasma-Cell | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-05-15